Ginkgo Bioworks To Present New Data on High Throughput Pooled Screening Method to Discover Novel CAR-T Designs for Solid Tumors
Ginkgo Bioworks (NYSE: DNA) announced a poster presentation at the Society for Immunotherapy of Cancer (SITC) on November 11, showcasing their innovative methods for discovering novel Chimeric Antigen Receptor (CAR) designs with improved persistence. The presentation highlights high throughput screening of CAR domains in human T cells, aiming to create effective CAR-T therapies for solid tumors, which make up 90% of adult cancers. The findings suggest that Ginkgo's platform can enable broader exploration and development of CAR-T therapies, addressing challenges like T cell exhaustion.
- None.
- None.
Poster presentation at SITC 2022 highlights high throughput methods for discovery of novel CAR designs with improved persistence
BOSTON, Nov. 9, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced that it will be presenting a poster on November 11 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The poster highlights Foundry-enabled methods for large-scale, combinatorial library design and screening of Chimeric Antigen Receptor (CAR) domains for improved persistence. The ability to screen hundreds of thousands of CAR designs in primary human T cells can enable discovery of variants with desired characteristics. This capability has the potential to discover CAR-T therapies that are effective against solid tumors.
CAR-T cell therapies show tremendous promise for the treatment of cancer. However, their use to date has been limited to targeting blood cancers, as CAR-T has failed to show consistent efficacy in treating solid tumors, which represent approximately
Signaling cascades triggered by intracellular domains (ICDs) of CARs drive T cell behaviors that correspond to different therapeutic outcomes, including CAR-T persistence. Systematic design and testing of novel ICD combinations that drive more favorable T cell phenotypes has been onerous due to technical constraints in high throughput screening. Data presented at SITC will demonstrate that Ginkgo's high throughput screening method enables massively parallel testing of CAR designs, and has led to discovery of new ICD combinations that outperform the canonical CD28-CD3z and 4-1BB-CD3z combinations.
Ginkgo's platform for cell programming enables synthesis and screening of diverse libraries of genetic constructs to explore biological space. Applying these capabilities to the design of CARs enables screening of hundreds of thousands of possible combinatorial variants of different CAR ICDs. Data presented at SITC will show how this method could be used to screen for variants with increased persistence in a serial tumor rechallenge assay. As an enabling platform company, Ginkgo can leverage its full stack of mammalian cell engineering expertise and capabilities to enable the high throughput screening of CAR-T cells to discover and optimize future next generation therapeutic candidates for its partners.
"While innovation in CAR-T cell therapies continues to grow at a dramatic pace, CAR-T is still a relatively new modality whose potential is just beginning to be fully explored," said Shawdee Eshghi, Senior Director, Mammalian Engineering, Ginkgo Bioworks. "With large scale screening and automation, Ginkgo has created a tool we believe can dramatically expand the variety and functionality of CAR domains so that our partners can build therapies targeted for particular tumor environments."
"We've only seen a small sliver of what revolutionary modalities like CAR-T can achieve in terms of patient outcomes. Being able to explore broader design space for this powerful technology can help unlock new potential in solid tumor treatment, inflammatory and autoimmune diseases, and beyond." said Arie Belldegrun, Executive Chairman and Co-Founder of Allogene Therapeutics and Kite Therapeutics and member of the Board of Directors for Ginkgo Bioworks. "The scale of Ginkgo's platform helps to enable discovery and innovation in this important arena."
To view the poster, please visit Ginkgo's blog. To learn more about SITC, to register, or to attend the poster presentation, visit www.sitcancer.org/2022.
Presentation details:
Date & Time: Friday, November 11, 2022 at 9 am - 8:30 pm, EST
Title: Pooled screening platform for discovering the next generation Chimeric Antigen Receptors
Presenting Author: Taeyoon Kyung, PhD, Senior Mammalian Engineer, Ginkgo Bioworks
Poster Number: 242
Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization and therapeutics discovery. For more information, visit www.ginkgobioworks.com.
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding Ginkgo's ability to expand the variety and functionality of CAR domains, screen hundreds of thousands of CAR designs in primary human T cells to enable discovery of variants with desired characteristics, and create a capability that has the potential to discover CAR-T therapies that are effective against solid tumors, and the potential success of Ginkgo's cell programming platform. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) the effect of Ginkgo's business combination with Soaring Eagle Acquisition Corp. ("Soaring Eagle") on Ginkgo's business relationships, performance, and business generally, (ii) risks that the business combination disrupts current plans of Ginkgo and potential difficulties in Ginkgo's employee retention, (iii) the outcome of any legal proceedings that may be instituted against Ginkgo related to its business combination with Soaring Eagle, (iv) volatility in the price of Ginkgo's securities now that it is a public company due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, changes in laws and regulations affecting Ginkgo's business and changes in the combined capital structure, (v) the ability to implement business plans, forecasts, and other expectations after the completion of the business combination, and identify and realize additional opportunities, (vi) the risk of downturns in demand for products using synthetic biology, (vii) the unpredictability of the duration of the COVID-19 pandemic and the demand for COVID-19 testing and the commercial viability of our COVID-19 testing business, (viii) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, and (ix) our ability to realize the expected benefits of merger and acquisition transactions. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the "SEC") on August 15, 2022 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.
GINKGO BIOWORKS INVESTOR CONTACT:
investors@ginkgobioworks.com
GINKGO BIOWORKS MEDIA CONTACT:
press@ginkgobioworks.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-to-present-new-data-on-high-throughput-pooled-screening-method-to-discover-novel-car-t-designs-for-solid-tumors-301672550.html
SOURCE Ginkgo Bioworks
FAQ
What is Ginkgo Bioworks presenting at SITC 2022?
When is Ginkgo Bioworks' presentation at SITC 2022?
What challenges do CAR-T therapies face in treating solid tumors?
How does Ginkgo's platform enhance CAR-T therapy development?
What is the significance of Ginkgo Bioworks in cancer treatment?
